Segantii Capital Management LTD Biogen Inc. Transaction History

Segantii Capital Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	BUY	$275.25 - $318.06 $27.5 Million - $31.8 Million	100,000 New	100,000 $28.5 Million
Q4 2022 Jan 30, 2023	BUY	$252.44 - $306.72 $5.05 Million - $6.13 Million	20,000 Added 100.0%	40,000 $11.1 Million
Q3 2022 Nov 08, 2022	BUY	$194.69 - $268.46 $3.89 Million - $5.37 Million	20,000 New	20,000 $5.34 Million
Q1 2022 Apr 26, 2022	SELL	$193.77 - $244.14 $1.26 Million - $1.58 Million	-6,479 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$259.0 - $414.71 $54,649 - $87,503	211 Added 3.37%	6,479 $2.24 Million
Q1 2021 May 11, 2021	SELL	$242.95 - $284.63 $1.43 Million - $1.68 Million	-5,900 Reduced 48.49%	6,268 $1.75 Million
Q4 2020 Jan 27, 2021	BUY	$236.26 - $355.63 $2.87 Million - $4.33 Million	12,168 New	12,168 $2.98 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Segantii Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Segantii Capital Management LTD with notifications on news.